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nents over baseline. On the Bosch calculated single index,
cilostazol was better than pentoxifylline and placebo.
Pentoxifylline had a lower calculated QALY score than
cilostazol or placebo. Based on this model, cilostazol had
an incremental cost per QALY of $72,153 over placebo
and $21,294 over pentoxifylline. As expected the model
is sensitive to changes in price and utilities, and patients
who have substantial improvements in QOL scores over
baseline have better cost per QALY results. From a man-
aged care perspective with a patient co-pay of 20%, the
patient’s incremental cost of cilostazol over placebo was
$14,431 per QALY and the managed care plan cost is
$57,722 per QALY. CONCLUSION: Based on this anal-
ysis of treatments for intermittent claudication, cilostazol
had a reasonable incremental cost per QALY over pen-
toxifylline or placebo. Lower cost per QALY results can
be obtained by continuing on therapy patients who attain
higher than average gains in quality of life scores from
baseline.
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OBJECTIVE: Patient compliance is an important com-
ponent in the successful management of any disease. In
general, it is assumed that in disease states involving peri-
odic, intense pain, such as angina pectoris (AP), com-
pliance rates would be high, and unaffected by dosing
regimen. We verified this hypothesis by examining the
compliance rates of patients taking different formulations
(o.d. (200–300mg), b.d. (90–120mg) and t.d.s. (60mg))
of diltiazem (princeps) for AP. METHOD: We performed
a retrospective analysis of 3455 electronic patient records
with a diagnosis of AP and a prescription of diltiazem
(princeps) from June 1st 1997 to June 1st 1998 (Medi-
plus-IMS Health) with a one-year follow-up. The above
patient cohort was then divided into 3 subgroups accord-
ing to the different formulation taken. The two sub-
groups b.d. and t.d.s. were paired to the third one, ac-
cording to 4 criteria: age, sex, disease history and co-
morbidities. Compliance was assessed using initial pre-
scription and refill rates ((pills dispensed/daily dose)/du-
ration of therapy). RESULTS: The proportion of patients
showing “good compliance” ( 0.8) was significantly
higher for the o.d. versus b.d. (36.1% versus 25.9%, p 
0.001) and for the o.d. versus t.d.s. (36.1% versus
27.1%, p  0.008). We observed the same trend when
we compared the mean rate of compliance for the o.d.
versus b.d. (0.62 versus 0.55, p  0.0027) and for the
o.d. versus t.d.s. (0.62 versus 0.60, p  0.0121). CON-
CLUSION: Even for life threatening cardiac disease like
AP, dosing regimens have a significant effect on compli-
ance. Giving diltiazem as an o.d. formulation could sig-
nificantly improve compliance and potentially decrease
health care resources used.
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OBJECTIVE: To examine the cost of illness of Conges-
tive Heart Failure (CHF) in the Louisiana Medicaid pro-
gram. METHODS: Study design: A retrospective review
of the medical and pharmacy claims data (1999–2000) in
the Louisiana Medicaid program. We reviewed pharmacy
and medical claims data for the years 1999–2000 from
the Louisiana Medicaid program. The data were ob-
tained from Unisys, the fiscal intermediary for the Louisi-
ana Medicaid program, in a PC compatible format. We
extracted the claims for CHF patients on the basis of the
ICD-9-CM codes. A total of 13,947 patients met the
study criteria, which included at least one primary or sec-
ondary diagnosis of CHF and availability of claims data
for at least one year after the first CHF diagnosis related
claim. We reviewed all the charges incurred for a one-
year period after the initial CHF claim. RESULTS: The
total cost for CHF patients for one year was over $182
million. The majority of the patients (73.63%) were fe-
male and accounted for 70% of the total cost. The mean
age was 70 years and the largest portion of the total cost
(55%) came from those 65 years and older. Of the
13,947 patients 11,065 (79%) were hospitalized at an
average cost of $4,679 per hospitalized patient. Approxi-
mately 87% of the study population received prescription
drugs at an average cost of $2,897 per prescription drug
user. Hospitalizations and prescription drugs contributed
28% and 19.38% respectively to the total cost. Almost
one third of the total cost was due to long-term care at
$13,817 per utilizer. Costs for CHF diagnosis related
claims were 14% of all costs. CONCLUSION: CHF rep-
resents a significant financial burden from the perspective
of the Louisiana Medicaid program. Improved manage-
ment of the condition is needed to reduce the cost of
treatment associated with CHF.
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Recent evidence suggests there is an increased risk of
rhabdomyolysis in patients initiated on cerivastatin com-
pared to patients initiated on other HMG CoA reductase
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inhibitors (HMGs). OBJECTIVE: The primary objective
is to determine if there are differences among specific
HMGs regarding the incidence of rhabdomyolysis. The
secondary objective is to identify significant risk factors
associated with rhabdomyolysis such as age, gender, and
concurrent gemfibrozil use. METHODS: Retrospective
pharmacy and medical claims from a large managed care
organization were analyzed. Patients were included if
they received any HMG (cerivastatin, fluvastatin, ator-
vastatin, lovastatin, pravastatin, or simvastatin) during
the period between 7/1/99 to 12/31/99. All patients were
followed for 6 months. ICD-9 diagnosis codes for rhab-
domyolysis (idiopathic), myalgia and myositis not other-
wise specified, or adverse effect to antilipemics were used
to define rhabdomyolysis events. RESULTS: There were
133,454 patients identified who received an HMG during
the identification period. The average age was 67.8 years
(S.D.  11.1) and 51.5% were female. The rates of rhab-
domyolysis with and without concurrent gemfibrozil use
were 0.861% and 0.632%, respectively (P  0.13).
Overall, the incidence across individual drugs was similar
for cerivastatin [0.486%(95%CI  0.363%–0.609%)],
fluvastatin [0.679%(95%CI  0.589%–0.769%)], ator-
vastatin [0.889%(95%CI  0.783%–0.995%)], lovasta-
tin [0.741%(95%CI  0.158%–1.332%)], pravastatin
[0.530%(95%CI  0.468%–0.592%)], and simvastatin
[0.378%(95%CI  0.212%–0.544%)]. With concurrent
gemfibrozil use, the incidence was significantly higher for
cerivastatin [6.341%(95%CI  3.005%–9.677%)] com-
pared to fluvastatin [0.713%(95%CI  0.000%–1.439%)],
atorvastatin [0.494%(95%CI  0.062%–0.926%)], lo-
vastatin (0.0%), pravastatin [0.452%(95%CI  0.091%–
0.813%)], and simvastatin (0.0%). In a logistic regres-
sion model, there was no significant relationship between
the incidence of rhabdomyolysis and age or gender.
CONCLUSION: In this population, it appears that the
risk of rhabdomyolysis is substantially higher when ceriv-
astatin is used concurrently with gemfibrozil. The find-
ings of this analysis indicate there is a substantial need
for managed care organizations and pharmacy benefits
management companies to proactively prevent the con-
current use of cerivastatin and gemfibrozil.
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OBJECTIVES: Trials of anticoagulation in non-rheu-
matic atrial fibrillation have demonstrated a reduction in
the risk of stroke by two-thirds. In these trials, the safety
of anticoagulation appeared good, but this may be re-
lated to highly selected patient groups. Exclusion rates of
93% were reported. Participants may have had fewer
complications than might be expected among less se-
lected patients in clinical practice. No trials had actually
looked at the costs of anticoagulation in a real day-to-day
clinical practice. The aim of this study is to investigate
the actual cost of warfarin treatment of atrial fibrillation
in a real clinical practice. METHODS: A one-year retro-
spective study involving patients of all ages admitted to
hospital with non-rheumatic atrial fibrillation on long-
term oral anticoagulation. Patients were interviewed and
their medical records reviewed. The costs of anticoagula-
tion were viewed as follows: 1. The cost of the active
drug. 2. The cost of monitoring the patient’s INR i.e.
traveling costs, staffing cost, and analysis costs. 3. The
costs associated with bleeding complications. RESULTS:
We studied 139 patients. The mean (SD) age was 73.6
(8.9) years, ranging from 41 to 93 years. The mean dura-
tion of oral anticoagulant therapy was 36 months (range
2 to 105 months), forming a total of 417 patient-years of
treatment. Mean (SD) INR was 2.5 (0.36). The target
range of 2.0–3.0 was achieved 54% of the time. Bleeding
occurred in 21 patients, with incidence of 7.2% per pa-
tient-year for minor bleeding, 2.4% per patient-year for
major bleeding and 0.2% for fatal bleeding. The cost of
warfarin tablets was £14.6 ($23.36), per patient-year,
but was £262.6 ($420.16), per patient-year after consid-
ering monitoring and bleeding complication costs. The
cost per stroke prevented was estimated at £8,141
($13,026). CONCLUSION: Anticoagulation appeared
safe and cost-effective in clinical practice but control was
not as good as in clinical trials.
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OBJECTIVES: To evaluate the quality of care given to
older patients hospitalised with heart failure and to iden-
tify areas in which treatment could be improved. METH-
ODS: A two-year retrospective study involving the analy-
sis of the case notes of a random sample of 145 elderly
patients (aged 
75 yrs) admitted to hospital with heart
failure. From The International Classification of Dis-
eases, we identified patients with a principle discharge di-
agnosis of heart failure (ICD codes 428.0-428.1-428.9).
Cases were excluded if the diagnosis could not be vali-
dated by medical record review. A total of one hundred
and forty five patients formed all the admissions with
heart failure during the study period. The standard of
care received was evaluated using the relevant quality of
care indicators derived from the Agency for Health Care
Policy and Research (AHCPR) Clinical Practice Guide-
lines. RESULTS: The study sample included 145 patients.
The mean age (SD) was 82 (5) years. Symptoms and signs
of heart failure were documented in 145 (100%) pa-
tients. All patients with symptoms and signs of hypervol-
aemia received diuretic therapy. Only fifty-five patients
(38%) had an objective assessment of left ventricular
